Mustang Bio (MBIO) Receives a Buy from B.Riley Financial
In a report released today, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Mustang Bio (MBIO), with a price target of $13.00. The company’s shares closed last Friday at $3.80.
According to TipRanks.com, Mamtani is a 5-star analyst with an average return of 28.9% and a 58.0% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Spectrum Pharmaceuticals, and Frequency Therapeutics.
Mustang Bio has an analyst consensus of Strong Buy, with a price target consensus of $10.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $5.22 and a one-year low of $2.42. Currently, Mustang Bio has an average volume of 1.91M.
Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of a broad range of proprietary chimeric antigen receptor engineered T cell (CAR T) immunotherapies and gene therapies. It develops CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as lentiviral gene therapy for XSCID. The firm’s products include MB-101 IL13Ra2-specific CAR, MB-102 CD123 CAR, MB-103 HER2 CAR, MB-104 CS1 CAR, MB-105 PSCA CAR, MB-106 CD20 CAR, MB-107 XSCID Gene Therapy and Oncolytic Virus (C134). The company was founded on March 13, 2015 and is headquartered in New York, NY.